MedPath

SiQHT19_Clinical performance study of the STANDARD™ i-Q COVID-19 Ag Home Test

Conditions
COVID 19
Registration Number
DRKS00029008
Lead Sponsor
SD Biosensor INC
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete
Sex
All
Target Recruitment
431
Inclusion Criteria

General inclusion criteria (for all study parts):
• The participant provided signed written informed consent prior to any study-specific procedure AND

Specific inclusion criteria:

• Part I, A + Part II, B
o SARS-CoV-2 positive patients AND
o Symptomatic subjects are recruited within seven days after the onset of symptoms OR within seven days from the viral infection (e.g. contact with a SARS-CoV-2 positive patient) OR

• Part I, B + Part II, A
o Apparently healthy subjects AND
o SARS-CoV-2 negative subjects

• Part II, C
o Subjects with unknown SARS-CoV-2 status, meaning that:
- Subject was not diagnosed SARS-CoV-2 positive / negative within the last 60 days AND
- Subject was not tested (e.g. self-test) for SARS-CoV-2 within the last 72 hours

Exclusion Criteria

General exclusion criteria:
• The participant is unwilling or unable to provide an informed consent OR
• Specimen type other than defined in the study protocol was collected (e.g. collection of oropharyngeal or throat samples) OR
• High risk patients such as emergency patients suffering from life-threatening injuries / sickness OR
• Subjects younger than 2 years

Specific exclusion criteria:
• Part I, B
o Patients/Subjects that were diagnosed positive for SARS-CoV-2 within the last 60 days (according to RKI)

• Part II
o Healthcare professionals regularly performing swab sample collection

• Part I, B + Part II, A
o Patients/Subjects that had contact within the last 14 days to a person that has been diagnosed positive for SARS-CoV-2 OR
o Patients/Subjects showing SARS-CoV-2 related symptoms

Study & Design

Study Type
observational
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Part I, ADiagnostic sensitivity > 80 % compared to the PCR-results<br>Part I, BDiagnostic specificity > 98 % compared to the PCR-results<br>Part II, B Diagnostic sensitivity > 80 % compared to the professional test result<br>Part II, C Diagnostic specificity > 98 % compared to the professional test result<br>Part II, A Result interpretationDetermination of the concordance of lay reading of contrived tests to the true result status of the respective pictures
Secondary Outcome Measures
NameTimeMethod
Part I, ADiagnostic sensitivity Demonstration of the sensitivity in relation to different viral load ranges:<br>• Ct = 25<br>• 25 < Ct = 30<br>• Ct > 30
© Copyright 2025. All Rights Reserved by MedPath